DDR1 Inhibition as a New Therapeutic Strategy for Colorectal Cancer

Molecular and Cellular Oncology- United Kingdom

doi 10.1080/23723556.2018.1465882

Full Text

Abstract

Available in

Date

Authors

Publisher

Informa UK Limited

Related search

RAD001 Offers a Therapeutic Intervention Through Inhibition of mTOR as a Potential Strategy for Esophageal Cancer

Oncology Reports
MedicineCancer ResearchOncology
2010English

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Targeting TCTP as a New Therapeutic Strategy in Castration-Resistant Prostate Cancer

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

New Therapeutic Agents for Metastatic Colorectal Cancer: Literature Review

Colorectal Oncology
2018English

Substrate-Selective COX-2 Inhibition as a Novel Strategy for Therapeutic Endocannabinoid Augmentation

Trends in Pharmacological Sciences
ToxicologyPharmacology
2014English

Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Targeting Tankyrase 1 as a Therapeutic Strategy for BRCA-associated Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Reverse Strategy for the Management of Rectal Cancer: A New Therapeutic Approach

Open Access Journal of Surgery
2017English

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy